Lacidipine Generics [uk] Ltd

Lacidipine, the active ingredient in Lacidipine Generics [uk] Ltd, is a calcium channel blocker presented as a generic oral formulation for oral use. It is employed to treat hypertension in adult patients requiring blood pressure control and is indicated for essential hypertension, often as part of combination therapy when monotherapy is insufficient.

GNH USA supplies Lacidipine Generics [uk] Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Lacidipine is used to manage high blood pressure by acting on the vascular system.

Hypertension: lowers elevated blood pressure, helping to reduce the risk of cardiovascular events such as stroke and myocardial infarction. Essential hypertension: provides sustained blood pressure reduction in patients with primary hypertension. Combination therapy for hypertension: can be combined with other antihypertensives to achieve target blood pressure when single‑agent therapy is inadequate.

Lacidipine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate headache, often transient and may improve with continued therapy. - Flushing: transient facial or neck flushing that usually resolves without intervention. - Peripheral edema: swelling of the ankles or feet, commonly mild and dose‑related. - Dizziness: sensation of light‑headedness or vertigo, particularly on standing.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction leading to fainting or syncope. - Hepatotoxicity: elevated liver enzymes or clinically apparent hepatitis requiring monitoring. - Allergic reactions: rash, pruritus, or rare anaphylactic response necessitating immediate medical attention.

When prescribing lacidipine, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular status: monitor patients with pre‑existing heart failure or unstable angina closely. - Renal impairment: adjust therapy cautiously in severe renal dysfunction. - Hepatic dysfunction: use with care in patients with liver disease and monitor liver function tests. - Concomitant antihypertensives: avoid excessive blood pressure lowering when combined with other vasodilators. - Pregnancy and lactation: contraindicated or not recommended unless benefits outweigh risks (consult guidelines). - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors: strong inhibitors such as ketoconazole or ritonavir may increase lacidipine plasma levels, raising risk of hypotension. - Grapefruit juice: can markedly raise drug concentrations and should be avoided.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood pressure lowering when combined with beta‑blockers, ACE inhibitors or diuretics; monitor BP. - CYP3A4 inducers: agents like rifampicin may reduce lacidipine effectiveness. - Calcium supplements: high calcium intake may diminish absorption; separate dosing times.